Information Provided By: 
Fly News Breaks for May 12, 2015
NLNK
May 12, 2015 | 08:04 EDT
Baird noted NewLink Genetics would continue its flagship IMPRESS trial as planned despite disclosing the FDA did not endorse management's plan to switch statistical methods midstream and the trial failed to show the required 30% OS improvement to stop early for efficacy. Baird expects the shares to open lower and would not be buyers, as they believe the chance of success of its algenpantucel-L trial has been lowered. Baird maintained its Neutral rating and $41 price target on NewLink Genetics shares.
News For NLNK From the Last 2 Days
There are no results for your query NLNK
